Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Sarcoma × pexidartinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Giant Cell Tumor of Tendon Sheath 5 Synovitis, Pigmented Villonodular 3 Neoplasms 2 Neoplasm Metastasis 2 Melanoma 2 Gastrointestinal Stromal Tumors 2 Breast Neoplasms 2 Triple Negative Breast Neoplasms 1 Stage I Prostate Adenocarcinoma 1 Solid Tumor 1 Sarcoma 1 Recurrence 1 Prostatic Neoplasms 1 Pathologic Complete Response 1 Pancreatic Neoplasms 1 Neurofibrosarcoma 1 Leukemia, Myeloid, Acute 1 Hodgkin Disease 1 Hemangiosarcoma 1 Glioblastoma 1 Colorectal Neoplasms 1 Advanced Solid Tumors 1

Interventions

Doxorubicin 119 Ifosfamide 70 Radiotherapy 64 Cyclophosphamide 61 Gemcitabine 53 Filgrastim 46 Docetaxel 34 pazopanib 33 Etoposide 33 pembrolizumab 32 Trabectedin 31 Vincristine 30 Cisplatin 29 Nivolumab 27 Irinotecan 21 Magnetic Resonance Spectroscopy 20 Carboplatin 20 Ipilimumab 19 Temozolomide 17 Radiation 16 Mesna 16 Melphalan 16 Bevacizumab 16 Sirolimus 15 Granulocyte Colony-Stimulating Factor 15 Dactinomycin 15 Biopsy 15 Topotecan 14 Surgical Procedures, Operative 14 Sorafenib 14

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02584647 2025-03-21

PLX3397

Columbia University

Phase 1/2 Terminated

39 enrolled 13 charts

Sarcoma, Neurofibrosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡